keyword
MENU ▼
Read by QxMD icon Read
search

Tnbc

keyword
https://www.readbyqxmd.com/read/29793177/long-noncoding-rna-gas5-suppresses-triple-negative-breast-cancer-progression-through-inhibition-of-proliferation-and-invasion-by-competitively-binding-mir-196a-5p
#1
Shuqin Li, Jun Zhou, Zhaoxin Wang, Peishun Wang, Xitao Gao, Yan Wang
Triple-negative breast cancer (TNBC) is considered to be the most aggressive and lethal type of breast cancer. Many studies have suggested that the dysfunction of long noncoding RNAs (lncRNAs) is correlated with breast cancer metastasis and progression. Here, we show that levels of the lncRNA, growth arrest-specific transcript 5 (GAS5), are decreased in TNBC tissues, and this down-regulation of GAS5 is associated with an aggressive tumor phenotype in patients, affecting clinical stage, lymph node metastasis and overall survival...
May 21, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29792857/tgf-%C3%AE-plays-a-vital-role-in-triple-negative-breast-cancer-tnbc-drug-resistance-through-regulating-stemness-emt-and-apoptosis
#2
Xiaodan Xu, Lu Zhang, Xiaogang He, Ping Zhang, Caihong Sun, Xiaojun Xu, Yaojuan Lu, Feifei Li
Triple negative breast cancer (TNBC) is the most malignant subtype of breast cancer in which the cell surface lacks usual targets for drug to exhibit its effects. Epirubicin (Epi) is widely used for TNBC, but a substantial number of patients develop Epi resistance that is usually associated with poor prognosis. Transforming growth factor (TGF-β) is a multifunctional cytokine. In recent study, it appears that TGF-β influences the cancer stem cell population, thus, the drug resistance of cancer may also be affected...
May 21, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29792166/the-pdgfr%C3%AE-erk1-2-pathway-regulates-cdcp1-expression-in-triple-negative-breast-cancer
#3
Luca Forte, Federica Turdo, Cristina Ghirelli, Piera Aiello, Patrizia Casalini, Marilena Valeria Iorio, Elvira D'Ippolito, Patrizia Gasparini, Roberto Agresti, Beatrice Belmonte, Gabriella Sozzi, Lucia Sfondrini, Elda Tagliabue, Manuela Campiglio, Francesca Bianchi
BACKGROUND: CDCP1, a transmembrane protein with tumor pro-metastatic activity, was recently identified as a prognostic marker in TNBC, the most aggressive breast cancer subtype still lacking an effective molecular targeted therapy. The mechanisms driving CDCP1 over-expression are not fully understood, although several stimuli derived from tumor microenvironment, such as factors present in Wound Healing Fluids (WHFs), reportedly increase CDCP1 levels. METHODS: The expression of CDCP1, PDGFRβ and ERK1/2cell was tested by Western blot after stimulation of MDA-MB-231 cells with PDGF-BB and, similarly, in presence or not of ERK1/2 inhibitor in a panel of TNBC cell lines...
May 23, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29791503/-18f-fdg-and-18f-flt-pet-for-the-evaluation-of-response-to-neo-adjuvant-chemotherapy-in-a-model-of-triple-negative-breast-cancer
#4
Isabella Raccagni, Sara Belloli, Silvia Valtorta, Alessandro Stefano, Luca Presotto, Claudio Pascali, Anna Bogni, Monica Tortoreto, Nadia Zaffaroni, Maria Grazia Daidone, Giorgio Russo, Emilio Bombardieri, Rosa Maria Moresco
RATIONALE: Pathological response to neo-adjuvant chemotherapy (NAC) represents a commonly used predictor of survival in triple negative breast cancer (TNBC) and the need to identify markers that predict response to NAC is constantly increasing. Aim of this study was to evaluate the potential usefulness of PET imaging with [18F]FDG and [18F]FLT for the discrimination of TNBC responders to Paclitaxel (PTX) therapy compared to the response assessed by an adapted Response Evaluation Criteria In Solid Tumors (RECIST) criteria based on tumor volume (Tumor Volume Response)...
2018: PloS One
https://www.readbyqxmd.com/read/29791287/brca1-2-mutations-and-bevacizumab-in-the-neoadjuvant-treatment-of-breast-cancer-response-and-prognosis-results-in-patients-with-triple-negative-breast-cancer-from-the-geparquinto-study
#5
Peter A Fasching, Sibylle Loibl, Chunling Hu, Steven N Hart, Hermela Shimelis, Raymond Moore, Christian Schem, Hans Tesch, Michael Untch, Jörn Hilfrich, Mahdi Rezai, Bernd Gerber, Serban Dan Costa, Jens-Uwe Blohmer, Tanja Fehm, Jens Huober, Cornelia Liedtke, Richard M Weinshilboum, Liewei Wang, James N Ingle, Volkmar Müller, Valentina Nekljudova, Karsten E Weber, Brigitte Rack, Matthias Rübner, Gunter von Minckwitz, Fergus J Couch
Purpose BRCA1/2 mutations are frequent in patients with triple-negative breast cancer (TNBC). These patients are often treated with primary systemic chemotherapy. The aim of this study was to analyze the effects of BRCA1/2 mutations on pathologic complete response (pCR) and disease-free survival (DFS) in a cohort of patients with TNBC treated with anthracycline and taxane-containing chemotherapy, with or without bevacizumab. Patients and Methods Germline DNA was sequenced to identify mutations in BRCA1 and BRCA2 in 493 patients with TNBC from the GeparQuinto study...
May 23, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29790898/ezh2-induces-the-expression-of-mir-1301-as-a-negative-feedback-control-mechanism-in-triple-negative-breast-cancer
#6
Qiuju Wu, Zekun Chen, Guihua Zhang, Wenhui Zhou, You Peng, Rong Liu, Ceshi Chen, Jing Feng
Breast cancer is one of the most common malignancies in women. ERα, PR, and HER2 triple negative breast cancer (TNBC) is the current research focus because of the lack of effective targeted therapies. In our study, lentivirus systems were used to overexpress EZH2 and miR-1301 in TNBC cell lines. Western blot analysis and RT-qPCR were used to detect the protein and microRNA levels. The TCGA and Kaplan Meier plotter databases were used to analyze the EZH2 and miR-1301 expression levels in breast cancer. The effect of miR-1301 overexpression on cell proliferation, migration and colony formation were determined by using the sulforhodamine B (SRB) assay, wound healing assay and colony formation assay, respectively...
May 22, 2018: Acta Biochimica et Biophysica Sinica
https://www.readbyqxmd.com/read/29790803/ultrasound-guided-delivery-of-thymidine-kinase-nitroreductase-dual-therapeutic-genes-by-pegylated-plga-pie-nanoparticles-for-enhanced-triple-negative-breast-cancer-therapy
#7
Rammohan Devulapally, Taehwa Lee, Aarohi Barghava-Shah, Thillai V Sekar, Kira Foygel, Sunitha V Bachawal, Jürgen K Willmann, Ramasamy Paulmurugan
AIM: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype. Since no targeted therapy is available, gene-directed enzyme prodrug therapy (GDEPT) could be an attractive strategy for treating TNBC. MATERIALS & METHODS:  Polyethylene glycol (PEG)ylated-poly(lactic-co-glycolic acid)/polyethyleneimine nanoparticles (PLGA/PEI NPs) were synthesized and complexed with TK-NTR fusion gene. Ultrasound (US) and microbubble (MB) mediated sonoporation was used for efficient delivery of the TK-NTR-DNA-NP complex to TNBC tumor in vivo for cancer therapy...
May 2018: Nanomedicine
https://www.readbyqxmd.com/read/29790419/rictor-gene-amplification-is-correlated-with-metastasis-and-therapeutic-resistance-in-triple-negative-breast-cancer
#8
Said El Shamieh, Fatima Saleh, Salim Moussa, Joseph Kattan, Fadi Farhat
Triple-negative breast cancer (TNBC) is characterized by its aggressive behavior, metastasis and lack of targeted therapies. Herein, we discuss the clinical, histopathological and genetic profile of a woman diagnosed with TNBC. Since the patient had no durable response to chemotherapy, a genetic profiling was carried out. Next-generation sequencing analysis of 592 genes showed a missense mutation, p.E545A in PIK3CA, thus the patient was started on the mTOR inhibitor everolimus, in combination with exemestane, which controlled her pain; however, the disease progressed aggressively...
May 23, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29786170/immunopeptidomic-profiling-of-hla-a2-positive-triple-negative-breast-cancer-identifies-potential-immunotherapy-target-antigens
#9
Nicola Ternette, Marloes J M Olde Nordkamp, Julius Muller, Amanda P Anderson, Annalisa Nicastri, Adrian V S Hill, Benedikt M Kessler, Demin Li
The recent development in immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cells in the treatment of cancer has not only demonstrated the potency of utilising T-cell reactivity for cancer therapy, but has also highlighted the need for developing new approaches to discover targets suitable for such novel therapeutics. Here we analysed the immunopeptidomes of 6 HLA-A2-positive triple negative breast cancer (TNBC) samples by nano-ultra performance liquid chromatography tandem mass spectrometry (nUPLC-MS2 )...
May 22, 2018: Proteomics
https://www.readbyqxmd.com/read/29786125/neoadjuvant-chemotherapy-use-in-breast-cancer-is-greatest-in-excellent-responders-triple-negative-and-her2-subtypes
#10
Brittany L Murphy, Courtney N Day, Tanya L Hoskin, Elizabeth B Habermann, Judy C Boughey
BACKGROUND: While breast cancer has historically been treated with surgery followed by adjuvant chemotherapy (AC) and radiation when indicated, neoadjuvant chemotherapy (NAC) use is thought to be increasing; however, the trends of its use in various biological subtypes have not been evaluated. We sought to evaluate the trend of NAC use over time by biological subtype. METHODS: We identified all patients with invasive breast cancer who underwent curative intent surgery and were treated with chemotherapy from 2010 to 2015 from the National Cancer Database...
May 21, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29783777/preferential-inhibition-of-wnt-%C3%AE-catenin-signaling-by-novel-benzimidazole-compounds-in-triple-negative-breast-cancer
#11
Abhishek Gangrade, Vibha Pathak, Corinne E Augelli-Szafran, Han-Xun Wei, Patsy Oliver, Mark Suto, Donald J Buchsbaum
Wnt/β-catenin signaling is upregulated in triple-negative breast cancer (TNBC) compared to other breast cancer subtypes and normal tissues. Current Wnt/β-catenin inhibitors, such as niclosamide, target the pathway nonspecifically and exhibit poor pharmacokinetics/pharmacodynamics in vivo. Niclosamide targets other pathways, including mTOR, STAT3 and Notch. Novel benzimidazoles have been developed to inhibit Wnt/β-catenin signaling with greater specificity. The compounds SRI33576 and SRI35889 were discovered to produce more cytotoxicity in TNBC cell lines than in noncancerous cells...
May 20, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29781719/serum-vitamin-d-status-and-breast-cancer-risk-by-receptor-status-a-systematic-review
#12
Jessica L Tommie, Susan M Pinney, Laurie A Nommsen-Rivers
BACKGROUND: The association between vitamin D status and breast cancer risk is equivocal. No systematic reviews or meta-analyses have examined this association stratified by receptor status. Our objective is to conduct a systematic review to answer the question, "Is there a relationship between lower serum/plasma vitamin D levels and increased risk of triple negative breast cancer (TNBC) specifically?" METHODS: We systematically searched Embase and PubMed databases for published original research studies examining the risk of a breast cancer diagnosis according to vitamin D status...
May 21, 2018: Nutrition and Cancer
https://www.readbyqxmd.com/read/29780974/metformin-targets-glucose-metabolism-in-triple-negative-breast-cancer
#13
R S Wahdan-Alaswad, S M Edgerton, H S Salem, A D Thor
Metformin is the most widely administered anti-diabetic agent worldwide. In patients receiving metformin for metabolic syndrome or diabetes, it reduces the incidence and improves the survival of breast cancer (BC) patients. We have previously shown that metformin is particularly potent against triple negative breast cancer (TNBC), with a reduction of proliferation, oncogenicity and motility, inhibition of pro-oncogenic signaling pathways and induction of apoptosis. These BCs are well recognized to be highly dependent on glucose/glucosamine (metabolized through anaerobic glycolysis) and lipids, which are metabolized for the production of energy and cellular building blocks to sustain a high rate of proliferation...
2018: Journal of Oncology Translational Research
https://www.readbyqxmd.com/read/29777999/targeted-delivery-of-cd44s-sirna-by-scfv-overcomes-de-novo-resistance-to-cetuximab-in-triple-negative-breast-cancer
#14
Wenyan Fu, Hefen Sun, Yang Zhao, Mengting Chen, Lipeng Yang, Xueli Yang, Wei Jin
The overexpression of EGFR often occurs in TNBC, and the anti-EGFR receptor antibody cetuximab is used widely to treat metastatic cancer in the clinic. However, EGFR-targeted therapies have been developed for TNBC without clinical success. In this study, we show that impaired EGFR degradation is crucial for resistance to cetuximab, which depends on the cell surface molecule CD44. To further investigate the role of CD44 in EGFR signaling and its treatment potential, we developed a targeting fusion protein composed of an anti-EGFR scFv generated from cetuximab and truncated protamine, called Ce-tP...
May 16, 2018: Molecular Immunology
https://www.readbyqxmd.com/read/29777630/microrna-493-is-a-prognostic-factor-in-triple-negative-breast-cancer
#15
Ling Yao, Yirong Liu, Zhigang Cao, Junjing Li, Yanni Huang, Xin Hu, Zhiming Shao
Breast cancer is one of the most common malignant diseases in women, in which triple-negative breast cancer (TNBC) exhibits higher aggressiveness and recurrence rates, while there are no effective targets or tailored treatments for patients with this subtype. Thus, finding effective prognostic markers for TNBC might help clinicians in their ability to care for their patients. We used tissue microarrays (TMAs) to detect miR-493 expression in breast cancer samples. A miRCURY LNATM detection probe specific for miR-493 was used in in situ hybridization assays...
May 19, 2018: Cancer Science
https://www.readbyqxmd.com/read/29777109/tak1-mediates-microenvironment-triggered-autocrine-signals-and-promotes-triple-negative-breast-cancer-lung-metastasis
#16
Oihana Iriondo, Yarong Liu, Grace Lee, Mostafa Elhodaky, Christian Jimenez, Lin Li, Julie Lang, Pin Wang, Min Yu
Triple-negative breast cancer (TNBC) is a highly metastatic subtype of breast cancer that has limited therapeutic options. Thus, developing novel treatments for metastatic TNBC is an urgent need. Here, we show that nanoparticle-mediated delivery of transforming growth factor-β1-activated kinase-1 (TAK1) inhibitor 5Z-7-Oxozeaenol can inhibit TNBC lung metastasis in most animals tested. P38 is a central signal downstream of TAK1 in TNBC cells in TAK1-mediated response to multiple cytokines. Following co-culturing with macrophages or fibroblasts, TNBC cells express interleukin-1 (IL1) or tumor necrosis factor-α (TNFα), respectively...
May 18, 2018: Nature Communications
https://www.readbyqxmd.com/read/29776832/an-sar-study-of-hydroxy-trifluoromethylpyrazolines-as-inhibitors-of-orai1-mediated-store-operated-ca-2-entry-in-mda-mb-231-breast-cancer-cells-using-a-convenient-fluorescence-imaging-plate-reader-assay
#17
Ralph J Stevenson, Iman Azimi, Jack U Flanagan, Marco Inserra, Irina Vetter, Gregory R Monteith, William A Denny
The proteins Orai1 and STIM1 control store-operated Ca2+ entry (SOCE) into cells. SOCE is important for migration, invasion and metastasis of MDA-MB-231 human triple negative breast cancer (TNBC) cells and has been proposed as a target for cancer drug discovery. Two hit compounds from a medium throughput screen, displayed encouraging inhibition of SOCE in MDA-MB-231 cells, as measured by a Fluorescence Imaging Plate Reader (FLIPR) Ca2+ assay. Following NMR spectroscopic analysis of these hits and reassignment of their structures as 5-hydroxy-5-trifluoromethylpyrazolines, a series of analogues was prepared via thermal condensation reactions between substituted acylhydrazones and trifluoromethyl 1,3-dicarbonyl arenes...
May 9, 2018: Bioorganic & Medicinal Chemistry
https://www.readbyqxmd.com/read/29774470/reproducibility-and-predictive-value-of-scoring-stromal-tumour-infiltrating-lymphocytes-in-triple-negative-breast-cancer-a-multi-institutional-study
#18
EDITORIAL
Mark O'Loughlin, Xavier Andreu, Simonetta Bianchi, Ewa Chemielik, Alicia Cordoba, Gábor Cserni, Paulo Figueiredo, Giuseppe Floris, Maria P Foschini, Päivi Heikkilä, Janina Kulka, Inta Liepniece-Karele, Peter Regitnig, Angelika Reiner, Ales Ryska, Anna Sapino, Aliaa Shalaby, Elisabeth Specht Stovgaard, Cecily Quinn, Elaine M Walsh, Vicky Zolota, Sharon A Glynn, Grace Callagy
BACKGROUND: Several studies have demonstrated a prognostic role for stromal tumour infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC). The reproducibility of scoring sTILs is variable with potentially excellent concordance being achievable using a software tool. We examined agreement between breast pathologists across Europe scoring sTILs on H&E-stained sections without software, an approach that is easily applied in clinical practice. The association between sTILs and response to anthracycline-taxane NACT was also examined...
May 17, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29772755/temozolomide-enhances-triple-negative-breast-cancer-virotherapy-in-vitro
#19
Rodolfo Garza-Morales, Roxana Gonzalez-Ramos, Akiko Chiba, Roberto Montes de Oca-Luna, Lacey R McNally, Kelly M McMasters, Jorge G Gomez-Gutierrez
Triple-negative breast cancer (TNBC) is one of the most aggressive types of cancer, and treatment is limited to chemotherapy and radiation. Oncolytic virotherapy may be a promising approach to treat TNBC. However, oncolytic adenovirus (OAd)-based mono-therapeutic clinical trials have resulted in modest outcomes. The OAd potency could be increased by chemotherapy-induced autophagy, an intracellular degradation system that delivers cytoplasmic constituents to the lysosome. In this study, the ability of alkylating agent temozolomide (TMZ)-induced autophagy to increase OAd replication and oncolysis in TNBC cells was evaluated...
May 17, 2018: Cancers
https://www.readbyqxmd.com/read/29771420/imp3-promotes-tnbc-stem-cell-property-through-mirna-34a-regulation
#20
Q-D Huang, S-R Zheng, Y-J Cai, D-L Chen, Y-Y Shen, C-Q Lin, X-Q Hu, X-H Wang, H Shi, G-L Guo
OBJECTIVE: To explore the expression and function of insulin-like growth factor II (IGFII) mRNA binding protein (IMP3) in the Triple Negative Breast Cancer (TNBC). MATERIALS AND METHODS: According to previously reported gene expression array, we found that IMP3 had significantly higher expression in the CD44+CD24-ESA+ cell cluster, tumor initiating cell or cancer stem cell (CSCs), compared to other tumor cells. Based on the GEO database (GEO accession No. GSE6883), we detected the mRNA levels of IMP 1,2 and 3 by quantitative polymerase chain reaction (q-PCR) in CD44+CD24-ESA+ cell cluster and other breast tumor cell clusters...
May 2018: European Review for Medical and Pharmacological Sciences
keyword
keyword
23272
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"